Skip to main content
Erschienen in: AIDS and Behavior 3/2019

22.02.2019 | Original Paper

Data-Driven Goals for Curbing the U.S. HIV Epidemic by 2030

verfasst von: Heather Bradley, Eli S. Rosenberg, David R. Holtgrave

Erschienen in: AIDS and Behavior | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Progress in reducing HIV infections has been suboptimal despite availability of effective prevention and treatment interventions and national strategies to bring them to scale. As part of a community-driven process, we expanded previous epidemiologic models using updated surveillance data from the Centers for Disease Control and Prevention to estimate quantitative parameters for ambitious but attainable national HIV prevention goals. We estimated new HIV infections could be reduced by up to 67% and prevalence could begin to decline by 2030 if 95% targets for diagnosis, care retention, and viral suppression are met by 2025 and an additional 20% of transmissions are averted through targeted interventions such as pre-exposure prophylaxis. Notably, this would require the percentage of diagnosed persons retained in HIV care to increase by more than 35 percentage points, which would necessitate innovative models and a substantial expansion of supportive services. Although the HIV incidence reduction goal of 90% as unveiled in the 2019 State of the Union Address is likely unachievable with the current intervention toolkit, it is possible to begin to substantially reduce HIV prevalence in the next decade with sufficient investments and innovation.
Literatur
1.
Zurück zum Zitat Centers for Disease Control and Prevention. HIV Surveill. Report. 2017;2018:29. Centers for Disease Control and Prevention. HIV Surveill. Report. 2017;2018:29.
2.
Zurück zum Zitat Singh S, Song R, Johnson AS, McCray E, Hall HI. HIV incidence, prevalence, and undiagnosed infections in U.S. men who have sex with men. Ann Intern Med. 2018;168(10):685–94.CrossRefPubMed Singh S, Song R, Johnson AS, McCray E, Hall HI. HIV incidence, prevalence, and undiagnosed infections in U.S. men who have sex with men. Ann Intern Med. 2018;168(10):685–94.CrossRefPubMed
3.
Zurück zum Zitat Shah M, Perry A, Risher K, et al. Effect of the US National HIV/AIDS Strategy targets for improved HIV care engagement: a modelling study. Lancet HIV. 2016;3(3):e140–6.CrossRefPubMedPubMedCentral Shah M, Perry A, Risher K, et al. Effect of the US National HIV/AIDS Strategy targets for improved HIV care engagement: a modelling study. Lancet HIV. 2016;3(3):e140–6.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations 2014. Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations 2014.
5.
Zurück zum Zitat Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438–47.CrossRefPubMed Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438–47.CrossRefPubMed
6.
7.
Zurück zum Zitat Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–81.CrossRefPubMed Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–81.CrossRefPubMed
8.
Zurück zum Zitat Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Gause NK, Brown JL, Welge J, Northern N. Meta-analyses of HIV prevention interventions targeting improved partner communication: effects on partner communication and condom use frequency outcomes. J Behav Med. 2018;41(4):423–40.CrossRefPubMed Gause NK, Brown JL, Welge J, Northern N. Meta-analyses of HIV prevention interventions targeting improved partner communication: effects on partner communication and condom use frequency outcomes. J Behav Med. 2018;41(4):423–40.CrossRefPubMed
11.
Zurück zum Zitat Hergenrather KC, Emmanuel D, Durant S, Rhodes SD. Enhancing HIV prevention among young men who have sex with men: a systematic review of HIV behavioral interventions for young gay and bisexual men. AIDS Educ Prev. 2016;28(3):252–71.CrossRefPubMed Hergenrather KC, Emmanuel D, Durant S, Rhodes SD. Enhancing HIV prevention among young men who have sex with men: a systematic review of HIV behavioral interventions for young gay and bisexual men. AIDS Educ Prev. 2016;28(3):252–71.CrossRefPubMed
12.
Zurück zum Zitat Laisaar KT, Raag M, Rosenthal M, Uuskula A. Behavioral interventions to reduce sexual risk behavior in adults with HIV/AIDS receiving HIV care: a systematic review. AIDS Patient Care STDS. 2015;29(5):288–98.CrossRefPubMedPubMedCentral Laisaar KT, Raag M, Rosenthal M, Uuskula A. Behavioral interventions to reduce sexual risk behavior in adults with HIV/AIDS receiving HIV care: a systematic review. AIDS Patient Care STDS. 2015;29(5):288–98.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Perez A, Santamaria EK, Operario D. A systematic review of behavioral interventions to reduce condomless sex and increase HIV testing for Latino MSM. J Immigr Minor Health. 2018;20(5):1261–76.CrossRefPubMedPubMedCentral Perez A, Santamaria EK, Operario D. A systematic review of behavioral interventions to reduce condomless sex and increase HIV testing for Latino MSM. J Immigr Minor Health. 2018;20(5):1261–76.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68(3):337–44.CrossRefPubMed Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68(3):337–44.CrossRefPubMed
15.
Zurück zum Zitat Platt L, Minozzi S, Reed J, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545–63.CrossRefPubMed Platt L, Minozzi S, Reed J, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545–63.CrossRefPubMed
16.
Zurück zum Zitat White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States 2010. White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States 2010.
17.
Zurück zum Zitat White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: updated to 2020 2015. White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: updated to 2020 2015.
18.
Zurück zum Zitat Joint United Nations Programme on HIV/AIDS (UNAIDS). Fast-track: ending the AIDS epidemic by 2030. Geneva, Switzerland 2014. Joint United Nations Programme on HIV/AIDS (UNAIDS). Fast-track: ending the AIDS epidemic by 2030. Geneva, Switzerland 2014.
21.
Zurück zum Zitat Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2010–2015. 2018. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 20102015. 2018.
23.
Zurück zum Zitat Bonacci RA, Holtgrave DRUSHIV. Incidence and transmission goals, 2020 and 2025. Am J Prev Med. 2017;53(3):275–81.CrossRefPubMed Bonacci RA, Holtgrave DRUSHIV. Incidence and transmission goals, 2020 and 2025. Am J Prev Med. 2017;53(3):275–81.CrossRefPubMed
24.
Zurück zum Zitat Hall HI, Green TA, Wolitski RJ, et al. Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis. J Acquir Immune Defic Syndr. 2010;55(2):271–6.CrossRefPubMed Hall HI, Green TA, Wolitski RJ, et al. Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis. J Acquir Immune Defic Syndr. 2010;55(2):271–6.CrossRefPubMed
25.
Zurück zum Zitat Skarbinski J, Rosenberg E, Paz-Bailey G, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015;175(4):588–96.CrossRefPubMed Skarbinski J, Rosenberg E, Paz-Bailey G, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015;175(4):588–96.CrossRefPubMed
26.
Zurück zum Zitat Jenness SM, Goodreau SM, Rosenberg E, et al. Impact of the centers for disease control’s HIV preexposure prophylaxis guidelines for men who have sex with men in the United States. J Infect Dis. 2016;214(12):1800–7.CrossRefPubMedPubMedCentral Jenness SM, Goodreau SM, Rosenberg E, et al. Impact of the centers for disease control’s HIV preexposure prophylaxis guidelines for men who have sex with men in the United States. J Infect Dis. 2016;214(12):1800–7.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Sullivan PS, Giler RM, Mouhanna F, et al. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017. Ann Epidemiol. 2018;28(12):833–40.CrossRefPubMedPubMedCentral Sullivan PS, Giler RM, Mouhanna F, et al. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017. Ann Epidemiol. 2018;28(12):833–40.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018;28(12):850–7.CrossRefPubMed Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018;28(12):850–7.CrossRefPubMed
29.
Zurück zum Zitat Bonacci RA, Holtgrave DR. Simplified estimates of HIV incidence and transmission rates for the USA, 2008-2012. AIDS. 2016;30(2):332–3.CrossRefPubMed Bonacci RA, Holtgrave DR. Simplified estimates of HIV incidence and transmission rates for the USA, 2008-2012. AIDS. 2016;30(2):332–3.CrossRefPubMed
30.
Zurück zum Zitat Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data: United States and 6 dependent areas, 2016. HIV Surveill Suppl Rep. 2018;23(4):1065–72. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data: United States and 6 dependent areas, 2016. HIV Surveill Suppl Rep. 2018;23(4):1065–72.
31.
Zurück zum Zitat Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–9.CrossRefPubMedPubMedCentral Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–9.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Craw J, Gardner L, Rossman A, et al. Structural factors and best practices in implementing a linkage to HIV care program using the ARTAS model. BMC Health Serv Res. 2010;10:246.CrossRefPubMedPubMedCentral Craw J, Gardner L, Rossman A, et al. Structural factors and best practices in implementing a linkage to HIV care program using the ARTAS model. BMC Health Serv Res. 2010;10:246.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Higa DH, Crepaz N, Mullins MM, Prevention Research Synthesis Project. Identifying best practices for increasing linkage to, retention, and re-engagement in HIV medical care: findings from a systematic review, 1996–2014. AIDS Behav. 2015;24:951–66. Higa DH, Crepaz N, Mullins MM, Prevention Research Synthesis Project. Identifying best practices for increasing linkage to, retention, and re-engagement in HIV medical care: findings from a systematic review, 1996–2014. AIDS Behav. 2015;24:951–66.
35.
Zurück zum Zitat Mizuno Y, Higa DH, Leighton CA, Roland KB, Deluca JB, Koenig LJ. Is HIV patient navigation associated with HIV care continuum outcomes? AIDS. 2018;32(17):2557–71.PubMed Mizuno Y, Higa DH, Leighton CA, Roland KB, Deluca JB, Koenig LJ. Is HIV patient navigation associated with HIV care continuum outcomes? AIDS. 2018;32(17):2557–71.PubMed
36.
Zurück zum Zitat Jain KM, Maulsby C, Kinsky S, Charles V, Holtgrave DR, Team PCI. 2015–2020 national HIV/AIDS strategy goals for HIV linkage and retention in care: recommendations from program implementers. Am J Public Health. 2016;106(3):399–401.CrossRefPubMedPubMedCentral Jain KM, Maulsby C, Kinsky S, Charles V, Holtgrave DR, Team PCI. 2015–2020 national HIV/AIDS strategy goals for HIV linkage and retention in care: recommendations from program implementers. Am J Public Health. 2016;106(3):399–401.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Maulsby C, Sacamano P, Jain KM, et al. Barriers and facilitators to the implementation of a national HIV linkage, re-engagement, and retention in care program. AIDS Educ Prev. 2017;29(5):443–56.CrossRefPubMedPubMedCentral Maulsby C, Sacamano P, Jain KM, et al. Barriers and facilitators to the implementation of a national HIV linkage, re-engagement, and retention in care program. AIDS Educ Prev. 2017;29(5):443–56.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Tucker JD, Tso LS, Hall B, et al. Enhancing public health HIV interventions: a qualitative meta-synthesis and systematic review of studies to improve linkage to care, adherence, and retention. EBioMedicine. 2017;17:163–71.CrossRefPubMedPubMedCentral Tucker JD, Tso LS, Hall B, et al. Enhancing public health HIV interventions: a qualitative meta-synthesis and systematic review of studies to improve linkage to care, adherence, and retention. EBioMedicine. 2017;17:163–71.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Bradley H, Viall AH, Wortley PM, Dempsey A, Hauck H, Skarbinski J. Ryan white HIV/AIDS program assistance and HIV treatment outcomes. Clin Infect Dis. 2016;62(1):90–8.CrossRefPubMed Bradley H, Viall AH, Wortley PM, Dempsey A, Hauck H, Skarbinski J. Ryan white HIV/AIDS program assistance and HIV treatment outcomes. Clin Infect Dis. 2016;62(1):90–8.CrossRefPubMed
40.
Zurück zum Zitat Weiser J, Beer L, Frazier EL, et al. Service delivery and patient outcomes in Ryan White HIV/AIDS program-funded and -nonfunded health care facilities in the United States. JAMA Intern Med. 2015;175(10):1650–9.CrossRefPubMedPubMedCentral Weiser J, Beer L, Frazier EL, et al. Service delivery and patient outcomes in Ryan White HIV/AIDS program-funded and -nonfunded health care facilities in the United States. JAMA Intern Med. 2015;175(10):1650–9.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat AIDS United. Ending the HIV epidemic in the United States: a roadmap for federal action 2018. AIDS United. Ending the HIV epidemic in the United States: a roadmap for federal action 2018.
Metadaten
Titel
Data-Driven Goals for Curbing the U.S. HIV Epidemic by 2030
verfasst von
Heather Bradley
Eli S. Rosenberg
David R. Holtgrave
Publikationsdatum
22.02.2019
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 3/2019
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-019-02442-7

Weitere Artikel der Ausgabe 3/2019

AIDS and Behavior 3/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Isotretinoin-Therapie kann in seltenen Fällen Albträume hervorrufen

13.06.2024 Akne Nachrichten

Isotretinoin ist zwar eine hochwirksame Behandlung bei Akne, wird aber mit einer Reihe potenzieller neuropsychiatrischer Nebenwirkungen, einschließlich Stimmungsschwankungen, in Verbindung gebracht. Dermatologen aus den USA berichten aktuell auch von Albträumen, die ihre Patientinnen erlebten.

Resektabler Speiseröhrenkrebs: FLOT schlägt CROSS

13.06.2024 ASCO 2024 Kongressbericht

Die perioperative Chemotherapie mit dem FLOT-Regime verbessert gegenüber der neoadjuvanten Radiochemotherapie mit CROSS das Gesamtüberleben von Patientinnen und Patienten mit resektablen Adenokarzinomen der Speiseröhre. Das legen aktuelle Daten der ESOPEC-Studie nahe.

Twinkretine bewähren sich in der Therapie von MASH

Neue Ergebnisse von Phase-II-Studien mit zwei Twinkretinen belegen die positiven Effekte von Survodutid und Tirzepatid in der Behandlung von Patienten, die eine mit metabolischer Dysfunktion assoziierte Steatohepatitis (MASH) mit Fibrose aufweisen.

Wo Künstliche Intelligenz in der Onkologie eingesetzt wird

12.06.2024 ASCO 2024 Kongressbericht

Wie lässt sich mit Künstlicher Intelligenz die Krebsversorgung voranbringen? Drei Beispiele vom ASCO-Kongress zeigen, wo es funktionieren kann: bei der Risikoabschätzung, der Vorhersage des Therapie-Ansprechens und beim telefonischen Kontakt mit Patientinnen und Patienten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.